Document Detail

Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
MedLine Citation:
PMID:  12949887     Owner:  NLM     Status:  MEDLINE    
Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU). A total of 58 patients (29 PV, 14 ET, 12 IMF, 3 unclassified) had been treated with HU. Thirty-five of these patients had been treated with HU alone whereas 18 patients had received both HU and BU. The follow-up period was 7.8 years. Twenty-five patients had not been treated with HU. In this patient group, 4 patients had been treated with BU. The follow-up period was 10.5 years. In the HU-treated group (n = 58) 7 patients developed AML and 5 patients MDS. Five of the 12 patients had been treated with HU alone, and 4 patients had received both HU and BU. In the non-HU-treated group (n = 25) 1 patient with PV developed acute myeloid leukemia (AML). This patient had only been treated with phlebotomies. It is concluded that treatment with HU is leukemogenic, with an incidence of AML and MDS of approximately 14% when used alone. The incidence is markedly increased to about 30% when HU is preceded by treatment with BU. HU is not recommended for use in younger patients, in whom non-leukemogenic agents such as alpha-interferon and anagrelide should be used instead.
Iben Nielsen; Hans Carl Hasselbalch
Related Documents :
13426797 - The carcinolytic effect of actinomycin c; a report of clinical studies.
15193447 - Etv6/runx1 rearrangement in childhood b-precursor acute lymphoblastic leukemia with nor...
19454497 - Clinical and biological characteristics of adult biphenotypic acute leukemia in compari...
10374857 - Development of a simple, blood based lymphoproliferation assay to assess the clinical s...
8103827 - Behaviour during a cluster headache.
23197 - Antinuclear antibodies in patients receiving non-practolol beta-blockers.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of hematology     Volume:  74     ISSN:  0361-8609     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-09-01     Completed Date:  2003-10-02     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  26-31     Citation Subset:  IM    
Copyright Information:
Copyright 2003 Wiley-Liss, Inc.
Department of Hematology L, Rigshospitalet University Hospital, Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Alkylating Agents / adverse effects*
Busulfan / adverse effects*
Chronic Disease
Drug Therapy, Combination
Hydroxyurea / adverse effects*
Leukemia / chemically induced*
Middle Aged
Myelodysplastic Syndromes / chemically induced*
Myeloproliferative Disorders / drug therapy*,  genetics*
Philadelphia Chromosome*
Primary Myelofibrosis / chemically induced
Retrospective Studies
Survival Analysis
Reg. No./Substance:
0/Alkylating Agents; 127-07-1/Hydroxyurea; 55-98-1/Busulfan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregatio...
Next Document:  Localization of the iron transport proteins Mobilferrin and DMT-1 in the duodenum: the surprising ro...